ClinTec Starts Operations in Malawi
News Aug 16, 2012
ClinTec International has expanded its operations into Malawi, appointing its first highly experienced clinical research associates.
A top 5 pharmaceutical company with sales exceeding US$50 billion has selected ClinTec as its preferred partner for vaccine development in Africa and Asia, further enhancing ClinTec’s growing presence in the emerging markets of Africa, Asia and the Middle East. The global vaccines market has an estimated value of US$33.8 billion.
Africa is a pivotal region for the development of adult and paediatric vaccines against infectious diseases and ClinTec is well placed to participate in these programmes.
The company is in the process of recruiting highly skilled personnel with vaccine research experience to join its already established teams in Africa and Asia, in preparation for strong growth ahead from these geographic markets.
Vaccine development faces its own challenges associated with local immunization recommendations as well as stringent cold chain management.
ClinTec’s team has the experience and understanding of the local challenges involved in working effectively in Africa and Asia, whilst complying in full with international clinical research guidelines.
ClinTec, winner of the 2011 Queen’s Award for Enterprise, operates in over 40 countries to provide specialist clinical research personnel and support services to its clients, which includes 11 of the top 25 pharmaceutical companies.
ClinTec has grown organically since its inception in the UK in 1997, and has recently reported a 429 percent growth rate over the 5-year period from 2006 to 2011.
It was one of the first CROs to establish a presence in the Middle East and Africa and has continued to strengthen its presence in the emerging markets as well as the more traditional Western European clinical research marketplace.
Commenting on the opening of ClinTec’s Malawi operations, Dr Rabinder Buttar stated: “I am pleased with our continued expansion in Africa and see huge potential for the company in conducting large scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organizations, ClinTec continues to grow and win major new business from pharma companies. The company is continuing to expand into interesting new regions for clinical research. As the pharmaceutical industry increasingly focuses its drug development efforts on the emerging markets, ClinTec will closely partner with its clients, aligning its services and operations to fit with their needs”.
Academic Redesigns FDA-Approved MabThera to Treat ALSNews
Researchers have redesigned a portion of the FDA-apporved MabThera for better-targeted treatment of ALS.READ MORE
Liver Fluke Granulin Structural Fold Provides Wound Healing OpportunityNews
Researchers can now mass produce wound-healing peptides isolated from the spit of the human parasitic liver fluke, a worm that causes liver cancer and kills 26,000 people in Thailand each year.READ MORE
Biogen's MS Drug FAMPYRA Granted Standard Marketing Authorization in EUNews
Biogen's drug FAMPYRA improves walking for MS sufferers and has been granted standard marketing authorization.READ MORE